26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: Pooled results from two phase 3 studies

Abstract

Ruxolitinib cream is a Janus kinase (JAK) 1/JAK2 inhibitor in development for atopic dermatitis (AD), a highly pruritic inflammatory skin disease. Two phase 3 randomized controlled trials (TRuE-AD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment score of 2 or 3, and 3%–20% affected body surface area. Patients (N = 1249 in both studies combined; median age, 32 years; mean ± SD itch numerical rating scale [NRS] score, 5.1 ± 2.5) were randomized (2:2:1) to 0.75% ruxolitinib, 1.5% ruxolitinib, or vehicle cream (all twice daily) for 8 weeks of double-blinded treatment.